AdimrSC 2f
Alternative Names: AdimrSC-2f; Recombinant COVID-19 vaccine - Adimmune CorporationLatest Information Update: 28 Sep 2023
At a glance
- Originator Adimmune Corporation
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in Taiwan
- 26 Jul 2023 Adimmune Corporation completes a phase I/II trials in COVID-2019 infections (Prevention) in Indonesia (IM) (NCT05104489)
- 03 Jan 2022 Phase-I/II clinical trials in COVID-2019 infections (Prevention) in Indonesia (IM) (NCT05104489)